{
    "clinical_study": {
        "@rank": "8392", 
        "arm_group": [
            {
                "arm_group_label": "DCVAC/PCa Arm", 
                "arm_group_type": "Experimental", 
                "description": "DCVAC/PCA Experimental therapy"
            }, 
            {
                "arm_group_label": "Standard Therapy", 
                "arm_group_type": "No Intervention", 
                "description": "No Intervention"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether DCVAC/PCa  added after radical primary\n      prostatectomy can improve PSA doubling times for patients with localized Prostate Cancer."
        }, 
        "brief_title": "Phase II Study of DCVAC/PCa Added After Radical Primary Prostatectomy for Patients With Localized Prostate Cancer", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male 18 years and older\n\n          -  Histologically confirmed prostate adenocarcinoma Stage T1 or T2\n\n          -  Post radical Primary Prostatectomy\n\n          -  20% increase in PSA above nadir\n\n          -  Salvage radiotherapy na\u00efve with PSA increase within 2 years or after salvage\n             radiotherapy with PSA not higher than 1 ng/ml\n\n          -  Eastern Cooperative Oncology Group (ECOG)  0-2\n\n        Exclusion Criteria:\n\n          -  Confirmed brain and/or leptomeningeal metastases\n\n          -  Prior androgen deprivation therapy or orchiectomy for prostate cancer\n\n          -  Peripheral neuropathy of Common Toxicity Criteria (CTC) grade 2 or greater\n\n          -  Other uncontrolled intercurrent illness\n\n          -  Treatment with immunotherapy against PCa\n\n          -  Clinically significant cardiovascular disease\n\n          -  Active autoimmune disease requiring treatment"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 4, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02107404", 
            "org_study_id": "SP003"
        }, 
        "intervention": {
            "arm_group_label": "DCVAC/PCa Arm", 
            "description": "DCVAC/PCa Experimental therapy", 
            "intervention_name": "DCVAC/PCa", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Immunotherapy", 
            "Prostate Cancer (PCa)", 
            "Biological", 
            "Vaccine"
        ], 
        "lastchanged_date": "May 12, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Brno", 
                        "country": "Czech Republic"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hradec Kralove", 
                        "country": "Czech Republic"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jablonec nad Nisou", 
                        "country": "Czech Republic"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jihlava", 
                        "country": "Czech Republic"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kromeriz", 
                        "country": "Czech Republic"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mnisek pod Brdy", 
                        "country": "Czech Republic"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Novy Jicin", 
                        "country": "Czech Republic"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Olomouc", 
                        "country": "Czech Republic"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pelhrimov", 
                        "country": "Czech Republic"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Plzen", 
                        "country": "Czech Republic"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Praha 10", 
                        "country": "Czech Republic"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Praha 4", 
                        "country": "Czech Republic"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Praha 5", 
                        "country": "Czech Republic"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Praha 8", 
                        "country": "Czech Republic"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Uherske Hradiste", 
                        "country": "Czech Republic"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Usti nad Labem", 
                        "country": "Czech Republic"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Czech Republic"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized, Open-label, Parallel-group, Multi-centre Phase II Clinical Trial of Active Cellular Immunotherapy With Preparation DCVAC/PCa in Patients With Localized Prostate Cancer After Radical Primary Prostatectomy", 
        "overall_contact": {
            "email": "kapsa@sotio.com", 
            "last_name": "Richard Kapsa", 
            "phone": ": (+420) 2241 74448"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Czech Republic: State Institute for Drug Control", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in Prostate Specific Antigen (PSA) Doubling Time from randomization to week 40", 
            "safety_issue": "No", 
            "time_frame": "40  Weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02107404"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in PSA Doubling Time during Follow-up from week 40 to 2 years after randomization", 
                "safety_issue": "No", 
                "time_frame": "104 Weeks"
            }, 
            {
                "measure": "Frequency of Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "0, 2, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 52, 65, 78, 91, 104 weeks"
            }, 
            {
                "measure": "Proportion of Patients with Objective disease progression within 2 years", 
                "safety_issue": "No", 
                "time_frame": "104 Weeks"
            }, 
            {
                "measure": "Number of Patients requiring Salvage Therapy at 2 years", 
                "safety_issue": "No", 
                "time_frame": "104 Weeks"
            }, 
            {
                "measure": "Comparison of PSA Doubling Time in Treatment Phase with Immunotherapy with the Value Prior to Randomization", 
                "safety_issue": "No", 
                "time_frame": "104 Weeks"
            }
        ], 
        "source": "Sotio a.s.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sotio a.s.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}